Vanadium Compounds as PTP Inhibitors by Irving, E & Stoker, AW
molecules
Review
Vanadium Compounds as PTP Inhibitors
Elsa Irving and AndrewW. Stoker *
Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health,
30 Guilford Street, London WC1N 1EH, UK; elsa.irving.15@ucl.ac.uk
* Correspondence: a.stoker@ucl.ac.uk; Tel.: +44-020-7905-2244
Received: 30 November 2017; Accepted: 15 December 2017; Published: 19 December 2017
Abstract: Phosphotyrosine signaling is regulated by the opposing actions of protein tyrosine kinases
(PTKs) and protein tyrosine phosphatases (PTPs). Here we discuss the potential of vanadium
derivatives as PTP enzyme inhibitors and metallotherapeutics. We describe how vanadate in the V
oxidized state is thought to inhibit PTPs, thus acting as a pan-inhibitor of this enzyme superfamily.
We discuss recent developments in the biological and biochemical actions of more complex vanadium
derivatives, including decavanadate and in particular the growing number of oxidovanadium
compounds with organic ligands. Pre-clinical studies involving these compounds are discussed in the
anti-diabetic and anti-cancer contexts. Although in many cases PTP inhibition has been implicated,
it is also clear that many such compounds have further biochemical effects in cells. There also remain
concerns surrounding off-target toxicities and long-term use of vanadium compounds in vivo in
humans, hindering their progress through clinical trials. Despite these current misgivings, interest in
these chemicals continues andmany believe they could still have therapeutic potential. If so, we argue
that this field would benefit from greater focus on improving the delivery and tissue targeting of
vanadium compounds in order to minimize off-target toxicities. This may then harness their full
therapeutic potential.
Keywords: protein tyrosine phosphatases; PTP; vanadium; oxidovanadium; oxovanadium; vanadate;
BMOV; diabetes; cancer
1. Introduction
In this review, we will focus on vanadium-derived chemicals as broad-specificity PTP inhibitors.
We will discuss their use in pre-clinical models and look at their therapeutic potential in diseases such
as cancer and diabetes. We also highlight a range of associated caveats. For those readers interested
in more wide-ranging reviews of vanadium chemistry or comprehensive reviews of the growing
multitude of vanadium compounds, these have been recently discussed in some other excellent
reviews [1–4].
2. Protein Tyrosine Phosphatases (PTPs)
The successful existence of multicellular organisms relies on the ability of cells within them to
communicate with one another through biochemical signalling, thus regulating responses to both
intra- and extracellular stimuli. Reversible phosphorylation of tyrosine residues is a critical component
of this process, and one that is itself heavily regulated. The addition and removal of phosphate groups
is catalysed by two classes of enzymes, the protein tyrosine kinases (PTKs) for phosphorylation and
the protein tyrosine phosphatases (PTPs) for dephosphorylation. Given the pivotal role of PTKs and
PTPs in cell signalling, it is unsurprising that disruption to their normal regulation results in abnormal
proliferation, survival, motility, differentiation and metabolism, underlying the pathogenesis of a range
of human diseases and rendering these enzymes as promising therapeutic targets [5].
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2.1. PTP Superfamily
PTPs are characterised by their active site cysteine residues, which act as critical nucleophiles
during catalysis [5,6]. The PTP superfamily is made up of 107 human genes. However, of these only 81
dephosphorylate phosphotyrosine. Of the remaining 26, 13 dephosphorylate inositol phospholipids,
two act on mRNA, and 11 are probably catalytically inactive [7]. They can be further subdivided into
four sub-families based on the amino acid sequence of their active sites, and have differing substrate
specificities (Figure 1).
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Figure 1. Protein tyrosine phosphatase (PTP) superfamily. Class 1-IV PTPs detailed in inner rings, 
with their substrate specificities stated in the outer ring. 
2.2. PTP Inhibition 
The roles of PTKs and PTPs in the pathogenesis of a wide range of human disease has long been 
appreciated and there has been significant progress in the field of kinase inhibition in the last few 
decades. There are over two dozen kinase inhibitors already on the market, as well as many 
therapeutic antibodies directed at kinases [8]. However, the development of drugs targeting specific 
PTPs has tended to lag behind, with no specific PTP inhibitors currently clinically approved. There are 
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Second, these kinases are often considered the main “drivers” of signalling [9,10]. There are also some 
technical factors that make targeting PTPs challenging. There is a high degree of sequence and 
structural similarity between family members, in particular at the active site containing the 
conserved HCX5R motif [5]. This results in difficulty in achieving a high degree of specificity when 
attempting to target specific PTPs [11]. Furthermore, the active sites of PTPs are much more polar than 
those of tyrosine kinases. Candidate inhibitor molecules that mimic substrates by competing for active 
site binding are thus usually charged or polar too, making them struggle to cross plasma membranes as 
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targeting both PTP active sites, and unique peripheral regions, which can specifically target 
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targeting both PTP active sites, and unique peripheral regions, which can specifically target individual
PTPs [11]. For example, trodusquemine (MSI-1436) is a non-competitive allosteric inhibitor of PTP1B,
currently in phase 1 clinical trials for breast cancer, and phase 2 trials for type 2 diabetes [12,13].
The general difficulty in developing specific PTP inhibitors though has commonly forced researchers in
the field to use non-selective pan-inhibitors, including in particular vanadium based compounds [14].
3. Vanadium
As aluded to above, a common experimental strategy for PTP inhibition has been to use classes of
molecules that act as pan-inhibitors of the whole enzyme family. Vanadium-derived compounds are
the clearest examples of these [15]. Vanadium is a group 5d transition metal present ubiquitously in
nature. It was discovered in 1830 by a Swedish chemist named Nils Gabriel Sefström and is the 18th
most abundant element in the Earth’s crust, found in soil, water, air and living organisms [16]. Within
many organisms vanadium is considered to be an essential micronutrient, and although this has yet
to be definitively applied to humans, it is likely that vanadium plays a regulatory role in human cell
function [17]. There has been considerable interest in the use of vanadium-based metallotherapeutics
to treat various diseases for many decades, most notably cancer and diabetes. Since 2000 there have
been over 1200 publications regarding vanadium and cancer or diabetes (PubMed). Whilst preclinical
studies have and continue to provide promising data and phase I and II trials have been completed,
an approved vanadium based drug has yet to reach the market. Below, we will discuss the reasons
behind this current, apparent barrier to wider vanadium usage, and potential ways forward.
3.1. Mechanisms of PTP Inhibition
Vanadium exists in oxidation states ranging from  III to +V, however, the majority of vanadium
in aqueous solutions is in the form of tetravalent vanadyl cations (IV) or pentavalent vanadate ions (V).
The orthovanadate ion has a tetra-coordinated structure and a negative charge, features that it shares
with the phosphate group of PTP substrates (Figure 2—structures 1 and 2). By mimicking phosphate,
orthovanadate fits into the PTP active site with trigonal pyramid geometry, stabilised by a complex
network of hydrogen bonds [15,18]. In this way, vanadate acts as a broad specificity, reversible and
competitive PTP inhibitor [18]. Some vanadium compounds, for example the peroxidovanadium
complexes, are also able to oxidise the critical active site cysteine residues, resulting in irreversible
inhibition [19,20]. For example mass spectrometric analysis of the human PTP LMW-PTP and
PTP1B treated with peroxidovanadium compound bisperoxo(1,10-phenanthroline)oxidovanadate(V)
(bpv-phen) (Figure 1—structure 3), revealed shifts in spectra consistent with active site cysteine
oxidation [15]. Note that hereafter we will refer to oxidovanadium compounds rather than oxovanadium,
as the former is now recommended by IUPAC nomenclature rules. Thus where we use the prefix “oxido-”,
readers need to be aware that previously published work often refers to “oxo-” for these chemicals.
Vanadium can also contribute to PTP inhibition indirectly. Interconversion between the vanadyl
(IV) and vanadate (V) redox states of the vanadium ion occur in the cell via Fenton-like reactions,
generating reactive oxygen species (ROS) [21,22]. These ROS can directly oxidise cysteine residues,
including the critical active site cysteines in PTPs. As these cysteines are essential to the enzymatic
mechanism of PTPs, their oxidation renders them catalytically inactive, sometimes irreversibly, hence
contributing to broad PTP inhibition [23,24].
Given that PTPs share a conserved consensus sequence at the catalytic site, including the critical
cysteine residue, it is reasonable to assume that vanadium compounds can inhibit all members of
the PTP superfamily [14]. For example, Peters et al. showed that the oxidovanadium derivative
bis(maltolato)oxidovanadium (IV) (BMOV) (Figure 2—structure 5) is able to inhibit class II LMW-PTP,
as well as both receptor and non-receptor classical class I PTPs, in an in vitro enzyme/substrate
competition assay [15]. Scrivens et al. also reported inhibition of dual specificity phosphatases (DSPs)
and both receptor and non-receptor class I PTPs using orthovanadate and bisperoxidovanadium (bpv)
compounds [20]. In relation to studies with the larger complexes generated with oxidovanadium,
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such as BMOV, it is very important to note that they are all likely to inhibit PTPs through orthovanadate,
a common degradation product. This has various consequences for their use as metallotherapeutics
and will be expanded upon below.
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There is an expanding repertoire of compounds containing monomeric vanadium co-ordinated
by different classes of organic ligands, including but n t limited to, maltolato vanadium compounds,
vandocenes, and peroxidovanadium complexes [16]. One key advantage of these larger complexes with
organic ligands seems to be improved bioavailability in vivo compared to vanadate [32,33]. However,
increasing evidence now suggests that these larger compounds often undergo a complex range of ligand
exchange events once in circulation and/or in the cell, ultimately releasing uncomplexed vanadate once
again as the active PTP-inhibiting moiety [3] (Figure 3). Peters et al. reported that the NMR shifts that
occur in LMW-PTP treated with either BMOV or sodium orthovanadate indicate changes in residues in
the P-loop of the active site that are virtually identical to one another, in icating that the same moiety,
t e uncomplexe vanadium, causes the changes in both [15]. They also analysed PTP1B crystals soaked
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It may therefore be true that no matter what the nature of the original vanadium complex, it may
be the derived, uncomplexed vanadate that is the active PTP inhibitor. Nevertheless, the continued
development of vanadium co-ordination complexes may still prove beneficial, by improving efficacy
through optimised vanadate bioavailability. Indeed vanadate accumulates in various tissues at 2–3
times higher concentration following BMOV treatment compared to vanadyl sulphate [34].
3.3. Ligand Toxicity
With a focus on the vanadate ion, there can be a danger of losing sight of the potential, cellular
actions of the organic ligands in vanadium complexes. In addition to BMOV studies (above), several
further studies have shown that vanadium compounds dissociate in vitro and in circulation to
release the ligating molecules, or modified forms thereof. This introduces complexity in defining
how oxidovanadium complexes work in vivo, in particular if the ligands themselves have cytotoxic
properties [3]. For example bis(4,7-dimethyl-1,10-phenanthroline)sulfatooxidovanadium(IV) (Metvan,
Figure 2—structure 6) was shown to induce anti-cancer properties, such as ROS-associated apoptosis
and loss of invasive properties, in a range of cancer cell lines within the nanomolar and lowmicromolar
range [35,36]. However, it was also shown that the ligands themselves generate a similar toxicity profile
in MTT assays of leukaemia cells [37]. Furthermore, it has now been shown that Metvan dissociates
in cell culture medium to release vanadium and free 1,10-phenanthroline (phen) ligands [38,39].
Treatment with these phen ligands alone results in similar cytotoxicity in a lung cancer cell line
(A549) compared to the whole Metvan complex. In this instance therefore, the tables are turned
and the vanadium may be largely acting as a carrier for these toxic ligands, rather than inducing
cytotoxicity itself. These ligands can also complex with copper and iron in the media, leading to
enhanced cellular uptake, where they increase ROS production, ultimately leading to cell death [40].
Systemic toxicity associated with phen ligand has also been demonstrated in vivo [38,41]. Therefore,
vanadium compounds containing such ligands are unlikely to be suitable for therapeutic applications
directed solely at PTP enzymes themselves.
This demonstrates the importance in considering the effect of all parts of vanadium complexes in
cells before prematurely assigning phenotypes as vanadium- or PTP-induced responses. In some cases
therefore, the differences in biological responses to the different classes of vanadium compounds may
actually be largely due to free systemic ligand effects [3]. Nevertheless, evidence indicates that some
vanadium complexes, including the sixfold octahedral complex with pentadentate phenolato ligands
described by Reytman et al. (Figure 2—structure 7), have a much higher stability in aqueous solution
and remain intact until after they have entered the cell [25]. This particular compound displayed
very high anticancer efficacy in vitro and in vivo. The pyridinone ligated oxidovanadium complexes
described by Rozzo et al. are also highly stable and are likely to remain intact until inside cells where
they exert anticancer activity [42]. Once inside the cell, the dynamics of complex dissociation and
the relative contributions of ligand toxicity or of vanadium-induced PTP inhibition to these cellular
responses is not yet known.
Overall, oxidovanadium in ligand complexes can be effective at increasing vanadium
bioavailability, but caution is advised concerning the nature of the ligands used and the interpretation
of biological responses.
4. Vanadium in Diabetes
Given its potential for modulating a wide range of signalling networks, vanadium is an attractive
candidate metallotherapeutic for the treatment of a range of human disorders. In fact there has
been interest in the medicinal properties of vanadium for many decades. The first reported case of
vanadium use in man was by Lyonnet et al. as far back as 1899. Sixty patients, three of whom were
diabetic, were given sodium metavanadate. A modest reduction in blood glucose was described
for two out of the three diabetics, and no adverse effects were reported [32]. This generated some
excitement surrounding the use of vanadium compounds to treat diabetic patients. However, this
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interest dwindled when insulin was discovered in 1922, quickly becoming the primary therapeutic
for diabetes [43]. During the 1950s and 1960s vanadium compounds were in clinical trials, not for
diabetes but for their ability to reduce cholesterol. Results from these trials in terms of efficacy
were disappointing; however, it is worth noting that side effects were limited to nausea, abdominal
pain, pharyngitis and anorexia, suggesting that vanadium compounds can be reasonably tolerated in
humans [44].
In the second half of the 20th century the insulin mimetic/enhancing activity of vanadium ions
began to be characterised, leading to suggestions again that vanadium compounds may indeed be able
to replace insulin injections, allowing patients to be treated with less invasive oral formulations [45].
This has resulted in a new wave of research interest in developing vanadium based compounds to
treat diabetes.
4.1. Insulin-Like Effects of Vanadium
Insulin signalling is critical for the clearance of glucose from the blood and to promote energy
storage in fat cells. High levels of blood glucose trigger insulin release from the beta cells of the pancreas.
Insulin binds to its cell surface receptor, inducing receptor autophosphorylation on specific tyrosine
residues. These phosphotyrosines become docking sites for Src homology 2 (SH2) domain containing
proteins including insulin receptor substrate 1 (IRS-1), in turn initiating signalling cascades ultimately
leading to translocation of glucose transporter type 4 (GLUT-4) channels to the plasma membrane
and increased glucose uptake. Insulin signalling can also promote glycogenesis, lipogenesis, and
protein synthesis, whilst inhibiting lipid breakdown and gluconeogenesis. Phosphotyrosine signalling
is heavily implicated throughout these signalling cascades, thus PTPs are highly relevant.
Normal insulin signalling is perturbed in diabetic patients, where either insulin can’t be produced
(type 1 diabetes) or the cellular response to insulin doesn’t function correctly (type 2 diabetes).
Vanadium-based compounds have resulted in reduced diabetic symptoms in animal models of
type 1 and 2 diabetes, and even in some human patients [45–49]. This is thought to be due
to the ability of vanadium to mimic insulin actions by inhibiting PTPs and in turn enhancing
phosphotyrosine signalling throughout the insulin signalling network [50]. In particular, vanadium
treatment increases phosphorylation of the insulin receptor, likely by inhibiting PTPs that ordinarily
cause dephosphorylation at these residues [15].
4.2. Clinical Trials
With an increasing bank of preclinical data in favour of vanadium-based diabetes therapeutics,
randomized clinical trials were carried out. Initially inorganic vanadium compounds such as vanadium
sulphate and ammoniummetavanadate were used [51–56]. However, these trials concluded that whilst
vanadium could be tolerated, with the main adverse effect reported as minor GI distress, efficacy in
diabetic patients was low and variability between patients was high [32,48]. This highlighted the need
for vanadium complexes with organic ligands that would allow fine-tuning of the vanadium response.
It was thought that a good ligand for vanadium complexes would prevent premature degradation of
the complex, allowing sufficient time for absorption into the blood stream and reduced toxicity such as
GI distress. Ideally, the complex should ultimately dissociate to leave the vanadium ion and an inert
ligand to be metabolised (Figure 3). Oxidovanadium complexes such as BMOV and closely related
bis(ethylmaltolato)oxidovanadium(IV) (BEOV) were thus introduced and dominated this field. In 2000
Medeval Ltd. (Manchester, UK) carried out a phase I clinical trial using BEOV administered orally in a
dose escalation between 25 and 90 mg. The trial confirmed that BEOV has improved pharmacokinetics
compared to vanadyl sulphate, both in terms of absorbance into circulation and increased half-life,
concluding that BEOV has a bioavailability three times higher than vanadyl sulphate. There was
evidence of tissue accumulation, although liver and kidney function remained normal. GI function was
also normal and no other adverse effects were observed [32]. Akesis Pharmaceuticals, Inc. (La Jolla,
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CA, USA) subsequently completed a phase IIa using seven type 2 diabetic patients dosed once a day
with 20 mg BEOV for 28 days. They reported reduced glucose levels with no major adverse effects [49].
Despite these apparently positive results, a systematic review published in 2008 stated that based
on data from current clinical trials, the use of vanadium to treat diabetes could not be recommended
since efficacy was too variable and side effects were consistently reported [48]. Additionally, the human
vanadium trials that have been reported thus far are short term only. A longer term safety study will
be required if this kind of therapy is to progress any further and potential, cumulative vanadium
toxicity, in particular in high phosphate tissues such as bone, would be a major focus [34,57].
5. Vanadium in Cancer
5.1. Phosphotyrosine Signalling in Cancer
Phosphotyrosine signalling is heavily implicated in virtually all aspects of cancer biology due to
its widespread influence over cell signalling. Alterations to normal phosphotyrosine signalling brought
about by mutations in relevant signalling molecules can drive the initiation and progression of many
different tumour types [58]. Therefore, therapeutic targeting of these pathways is an attractive avenue
for cancer treatment. In the past 30 years, several tyrosine kinases have been identified as oncogenes
that drive tumourigenesis, generating a rich source of druggable targets. Many small molecules and
biologics targeting kinases are already in the clinic [8].
PTPs were formally discovered in the late 1980s and at that point were still thought to function
as fairly unregulated housekeeping enzymes, negatively regulating phosphotyrosine signalling.
They were therefore labelled as candidate tumour suppressors. Some PTPs are indeed tumour
suppressors, including PTEN. PTEN is nevertheless quite specific in negatively regulating AKT
signalling and it is mutated in many humanmalignancies [59,60]. It is now clear that many, possibly all,
phosphatases are actually regulated signalling molecules that can positively contribute to the control
of phosphotyrosine signalling [58]. In fact rather than simply being suppressors, MacKeigan et al.
reported that nearly a third of PTPs may instead promote cell survival, making them potential cancer
drug targets [61]. A number of oncogenic PTPs have now been described, the first of which was SHP2.
Overexpression of SHP2 has been reported in leukaemia and breast cancer, and activatingmutations are
associated with childhood malignancies [62–64]. In breast cancer cell lines, shRNA-mediated inhibition
of SHP2 reversed epithelial-to-mesenchymal transition and reduced migration and invasion [65]. Other
PTPs such as PTP1b are also considered oncogenic in breast cancer models [66–68].
With the above in mind, there is now increasing interest in the development and use of PTP
inhibitors for anti-cancer therapeutics. Vanadium-based chemicals may represent one source of these.
5.2. Anti-Cancer Activity of Vanadium
Vanadium has long been of interest in cancer biology, with the first report of its anticancer activity
in 1965 [69]. Since then considerable research efforts have described the potential for vanadium-based
compounds in preventing the onset of tumourigenesis and in the treatment of cancers. Vanadium
compounds are able to inhibit cancer initiation and progression in model systems by acting against
several of Weinberg’s hallmarks of cancer, including inducing apoptosis or other cell death pathways,
reducing proliferation and inhibiting migration and metastasis [70]. The most successful cancer
therapies are those that target more than one aspect of tumour biology, therefore vanadium-derived
chemicals are seemingly very promising, multifunctional therapeutic candidates. In Tables 1 and 2
we summarize several studies reporting anti-cancer properties of a variety of vanadium compounds,
both in vivo and in vitro.
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Table 1. Summary of some reported anti-cancer activities of vanadium in cancer cell lines.
Tumour Cell Type Compound Effect Suggested Mechanism
Cervical [71] Nicotinoyl hydrazine vanadiumcomplexes (50–100 µM) Increased apoptosis p53 induction
Hepatocellular
carcinoma (HCC) [72] Sodium orthovanadate (15–30 µM)
Decreased Proliferation
G2/M arrest
Increased Apoptosis
Osteosarcoma [73,74] Oxidovanadium flavonoid complexes(10–100 µM)
Increased apoptosis
DNA damage
Cell cycle arrest
ROS production
DNA strand breaks
Osteosarcoma [75] Vanadium (IV) complexes (2.5–5 µM)
Reduced cell adhesion and
migration
Reduced colony formation
Reduced actin polymerisation
via suppressed PKA activity
Malignant melanoma
[42]
Pyridinone ligated oxidovanadium
complexes (1–100 µM)
Reduced proliferation
Increased apoptosis
Cell cycle arrest
Lung and Melanoma [76] Pyridoxylideneiminato vanadium(50 µM) Increased apoptosis ROS production
Lung and breast [77] Vanadium (V)-peroxido-betaine(25–50 µM)
Reduced migration
Increased cell death Reduced TGF mediated EMT
Lung and Breast [78] Vanadium-peroxido-betaine(100–400 µM)
Increased apoptosis
DNA damage
ROS production
Reduced HRAS and MMP2
expression
Breast [79] Ammonium monovanadate(100–250 µM) Apoptosis and cell cycle arrest
Breast [80] Vanadocene dichloride (10–20 µM) Reduced proliferationG2/M arrest
Glioma [81] Picolinato-bis(peroxido)oxidovanadate(V) (Bpv(pic)) (5–20 µM)
Reduced proliferation
S phase and G2/M accumulation
Increased apoptosis
Reduced migration and invasion
Inhibition of PTP expression
and activity
Rhabdomyosarcoma [82] BMOV and vanadium salts(10–40 µM) Growth inhibition
CML [83] VO-salen (6–32 µM)
Reduced proliferation
G2/M arrest
Chemosensitisation to taxol
Neuroblastoma [84,85] BMOV (10 µM) CytotoxicityDifferentiation PTP inhibition
Testicular [86] Vanadocene dichloride (100 µM) Apoptosis
Prostate [87] Vanadate (25–100 µM) G2/M arrestGrowth inhibition
ROS mediated
CDC25C degradation
Ovarian and Prostate
[88]
Heteroleptic Schiff base vanadium
complexes (1–150 µM) Cytotoxicity
Disrupted mitotic spindle
formation
Pancreas [89] Phenanthroline/quinolone ligatedvanadium (1–100 µM)
Increased apoptosis and
necroptosis
G2/M arrest
ROS production
Pancreas [90] Bis(acetylacetonato)-oxidovanadium(IV) (1–400 µM)
Reduced proliferation
G2/M arrest
ROS production
ERK pathway activation
Colorectal [91] Schiff base vanadium complex(20 µg/mL)
Increased apoptosis
G2/M arrest
GSH depletion
ROS production
DNA damage
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Table 2. Summary of some reported anti-cancer activities of vanadium in animal cancer models.
Model Compound Effect Suggested Mechanism
DEN rat liver model
[92–97]
Ammonium metavanadate
(0.5 ppm/4.27 µM in drinking water)
Chemopreventative—reduced
proliferation and premalignant
nodule incidence
Reduced DNA damage
Increased expression of drug
metabolising enzymes
2-AAF rat liver model
[98–100]
Ammonium
monovanadate/ammonium
metavanadate (0.5 ppm/4.27 µM in
drinking water)
Chemopreventative—reduced
tumour incidence, reduced
proliferation and increased
apoptosis
Reduced DNA damage
Increased expression of drug
metabolising enzymes
Induction of p53
Orthotopic
Hepatocellular
carcinoma mouse model
[72]
Sodium orthovanadate (10–20 mg/kg) Reduced cell proliferation andtumour volume
DMH rat colon model
[101,102]
Vanadium (0.5 ppm/4.27 µM in
drinking water)
Chemopreventative—reduced
proliferation, increased apoptosis
Reduced DNA damage
Induction of p53
DMH rat colon model
[103]
Ammonium monovanadate
(0.5 ppm/4.27 µM in drinking water)
Chemopreventative—reduced
tumour incidence Reduced DNA damage
MNU rat mammary
model [104] Vanadyl sulphate (25 ppm in feed)
Chemopreventative—reduced
tumour incidence and increase
survival
DMBA rat mammary
model [79,105–107]
Ammonium
monovanadate/ammonium
metavanadate (0.5 ppm/4.27 µM in
drinking water)
Chemopreventative—reduced
tumour incidence and size.
Reduced proliferation and
increased apoptosis
Reduced DNA damage
Induction of p53
DMBA rat mammary
model [108]
Ammonium monovanadate
(0.5 ppm/4.27 µM in drinking water)
Chemopreventative—reduced
tumour incidence, reduced
proliferation and increased
apoptosis
Reduced DNA damage
Induction of p53
DMBA rat mammary
model [109]
Ammonium monovanadate
(0.5 ppm/4.27 µM in drinking water)
Chemopreventative—reduced
tumour incidence
Increased expression of drug
metabolising enzymes
MDA-MB-231 mouse
breast cancer xenograft
model [35,36]
Metvan (10 mg/kg intraperitoneal) Reduced tumour progression andincreased apoptosis Induction of oxidative damage
DA3 mouse breast cancer
xenograft model [20]
Bisperoxidovanadium compounds
(20 mg/kg intraperitoneal) Reduced tumour growth
CDC25A inhibition leading to
cell cycle arrest and apoptosis
U87 mouse glioblastoma
xenograft model [35,36] Metvan (10 mg/kg intraperitoneal)
Reduced tumour progression and
increased apoptosis Induction of oxidative damage
L1210 injected mice
(leukemia) [110]
Vanadocene dichloride
(10–130 mg/kg) Increased life span
Many publications to date have described in vivo chemoprevention by vanadium-supplemented
drinking water in chemically induced cancer models of breast, colon and liver [79,95,102,107]. These
studies concluded that vanadium reduces tumour incidence, by up-regulation of drug metabolizing
enzymes, protection from DNA damage, and induction of the p53 response [111] (Table 2). Moreover,
various vanadium derived compounds were shown to be successful in inhibiting tumour development
in xenograft models for breast cancer, hepatocellular carcinoma, glioblastoma and leukaemia, through
their ability to inhibit PTPs and to induce oxidative damage, which itself likely contributes to PTP
inhibition [20,35,36,72,110].
A plethora of studies using cell culture models for various tumour types have corroborated
these findings and have begun to dissect the intracellular targets of vanadium compounds (Table 1).
These studies highlight the fact that vanadium is able to inhibit cancer cell phenotypes via multiple
nodes due to its ability to inhibit PTPs, be it directly or by ROS production, thus impacting on several
key signalling pathways. In many cases, reduced proliferation and increased apoptosis is reported
following vanadium treatment. For example, Ajeawung et al. reported that the vanadium compound
picolinato-bis(peroxido)oxidovanadate (V) (Bpv(pic)) is able to reduce proliferation, induce apoptosis
and inhibit migration in paediatric glioma cells by inhibiting activity and expression of specific PTPs
involved in these processes [81]. Wu et al. reported reduced proliferation caused by G2/M cell cycle
arrest in pancreatic cancer cells treated with bis(acetylacetonato)-oxidovanadium(IV), concluding that
ROS-mediated ERK pathway activation is required for these anticancer effects [90]. We have shown
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that BMOV induces differentiation and or cytotoxicity in neuroblastoma cell lines, most likely driven at
least in part by PTP inhibition [84,85]. There is also evidence that vanadium may be useful in reducing
the metastatic potential of cancer cells. Petandis et al. showed that a vanadium(V)-peroxido-betaine
complex can inhibit TGF mediated epithelial-mesenchymal transition (EMT) and reduces the tumour
cell migration in vitro [77]. There is published data indicating that decavanadate-based compounds
can also reduce tumour cell viability in vitro and in vivo, however, it is not clear whether this is due to
PTP inhibition or other effects of these compounds (discussed below) [4,112,113].
Clearly there is a large bank of preclinical data supporting anti-cancer activities of vanadium-based
compounds. Whilst many of these studies do not directly explore PTP inhibition as a mechanism
driving these properties, it is likely that many of the effects described are driven by PTP inhibition,
both directly by competitive inhibition by vanadate, and via ROS driven active site cysteine oxidation.
If this is correct, then it is worth pointing out that the beneficial effects of vanadium compounds must
be the net effect of inhibiting many PTPs.
5.3. Non-PTP Inhibition Mechanisms of Vanadium
Although vanadium compounds do inhibit PTPs [14], they also have other intracellular activity
that may contribute to their anti-cancer efficacy. First, vanadate also affects the active site function
of other phosphate-binding molecules such as ATPases, including ABC transporters [114]. Although
the mechanism of this inhibition may be distinct from that of PTPs, ATPases are a class of potential
off-target effectors [115]. Decavanadate also inhibits ATPases, including actin-stimulated myosin
ATPase and sarcoplasmic reticulum Ca2+ ATPase, but in this case through a distinct, allosteric,
non-competitive mechanism by binding to a site distinct from the ATP-binding pocket [4,26,27]).
Decavanadate also induces specific mitochondrial effects distinct from vanadate. It accumulates in
the mitochondria and alters mitochondrial antioxidant enzyme activities, as well as mitochondrial
membrane depolarization perhaps by acting on complex III cytochrome b [4,28,29]. These findings
suggest that decavanadates, like other oxidovanadium complexes, may have significant systemic
toxicities if they were to be used as therapeutic compounds. Although the mitochondrial effects
described above appear to be specific to decavanadate, they cannot be entirely discounted with respect
to monomeric vanadium complexes as there is some evidence suggesting that decavanadate may be
formed from vanadate and stabilized within cells [31,116].
As discussed previously, conversion from vanadyl to vanadate generates ROS [21]. This increase
in ROS may contribute to PTP inhibition; however, it may also contribute to cell death described in
some of the in vitro anti-cancer studies. Cancer cells often exist in a state of sub-lethal oxidative stress,
thus even small increases in ROS may have dramatic effects on tumour cell viability by damaging
DNA and lipids. Some vanadium compounds, in particular vanadocenes, can complex with DNA and
inhibit RNA and DNA synthesis, likely contributing to their anticancer efficacy [117,118].
5.4. Systemic Toxicities Associated with Vanadium
When administered orally, vanadium enters the circulation via absorption from the GI tract.
Once in the bloodstream, vanadium compounds undergo ligand exchange, and can become bound to
metabolites such as lactate and citrate, and proteins, predominantly transferrin [16,119]. Vanadium
can enter cells from the bloodstream via passive diffusion depending on the ligation of vanadium,
active transport through anion channels and possibly by endocytosis in the case of transferrin-bound
vanadium [3,120]. The relative abundance of vanadium in specific tissues is as follows; bone > kidney,
liver > blood > muscle > brain [34,82]. Unabsorbed vanadium exits the body in faeces, whereas
absorbed vanadium is eventually cleared in urine and from hair and skin loss. A small proportion
accumulates in high phosphate tissues such as the bone for long periods of time [32,57]. As mentioned
previously, this presents a potential safety concern in administering oxidovanadium as a therapeutic.
Although vanadium has not been classified by the International Agency for Research on Cancer
(IARC) as a carcinogen, there have been some reports that vanadium compounds can induce
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tumourigenesis, potentially due to increased ROS production [19]. A study by Ress et al. sought to
identify toxicity associated with long term exposure to airborne vanadium pentoxide in mice and rats,
and reported increased alveolar/bronchiolar neoplasms [121]. Although, the animals in this studywere
exposed for two years, therefore this is perhaps not applicable to short-term oxidovanadium treatment.
In very extreme cases of vanadium poisoning (6000 times higher than normal body concentration)
respiration can be inhibited resulting in fatality [122]. However, generally very few adverse effects
have been reported in animal models, and only GI distress, weight loss and anorexia in humans.
Systemic toxicity nevertheless continues to be a major factor discouraging the use of vanadium-based
compound in humans. This is clearly a greater issue for long-term use in diabetics, but perhaps less of
an issue for short-term treatment of cancer patients.
6. Future of Vanadium Research
Vanadium-based compounds have undoubtedly displayed promising properties relating to the
treatment of diabetes and cancer, as well as some other diseases [2]. However, concerns regarding
their safety as therapeutic agents in humans are significant. Initially it was hoped that developing
vanadium complexes with different organic ligands might reduce some of the systemic toxicity, whilst
enhancing the disease-treating properties. Indeed this may still be true in the case of highly stable
compounds. However, recent data demonstrate that in many cases vanadium complexes undergo
speciation in circulation and in target cells, releasing vanadium and ligands, in some cases bound to
other molecules [3,39]. As discussed previously, it is important then to consider the toxicity profiles of
the ligands themselves, as well as systemic toxicity associated with vanadium.
One way to potentially overcome issues surrounding the off-target toxicity of ligands and
oxidovanadium itself, is to package oxidovanadium compounds into nanoparticles or nanocomposites
that can be passively or actively targeted to cells. For example, packaging of vanadate with chitosan into
nanocomposite carriers has been demonstrated, and these have been used for diabetes studies [123,124],
whereas Kremer and co-workers have successfully crosslinked oxidovanadium into complexes with
anionic polysaccharides [125]. Chen et al. were able to package vanadium disulphide nanodots into
PEG lipid micelles, which displayed high tumour uptake in tumour-bearing mice [126]. Although
these latter nanocarriers were developed to be used for image guided photo thermal cancer therapy,
this study does demonstrate the principle that vanadium compounds could be packaged into
nanocarriers for delivery to tumour cells. Cancer is an appealing area for the use of nanocarriers due
to the enhanced permeability and retention effect (EPR) in solid tumours, where nano-sized particles
of under 200 nm are favourably delivered to and accumulate in tumour tissue due to its increased
vasculature permeability [127,128]. It may even be feasible to employ V2O5 nanocrystals in this way,
as they too can be formed into 100 nM particles [129], although it is unclear how these would behave
in vivo. By reducing off-target, systemic toxicity of vanadium, one could better harness vanadium’s
anti-PTP actions. Encapsulating drug complexes also means that degradation in the circulation can be
reduced, further concentrating the amount of active complex reaching the target tissue. If deliberately
used in this manner, one could envisage the design of bi-potential oxidovanadium complexes whereby
cells would be subjected to both the anti-cancer effects of the PTP-inhibitory vanadate plus the cytotoxic
ligands, generating additive or synergistic anti-cancer effects (Figure 3).
In summary, although there are significant caveats hindering the use of current vanadium-based
therapeutics, there are good reasons why this field should maintain its efforts. With new technologies
for drug delivery constantly becoming available, several of the less advantageous effects of vanadium
could become avoidable, raising the opportunity for development of truly effective and safe drugs
based on this transition metal and its attractive, flexible chemistry.
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